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Background
MKD is an autosomal recessive disease caused by muta-
tions in the mevalonate kinase (MVK) gene.
Aim
To analyze the long term follow-up and health related
quality of life (HRQL) in MKD.
Methods
MVK gene was analyzed in 950 consecutive patients
with periodic fever. 40 MKD patients were identified.
Spontaneous disease course was classified as follows: i)
resolution (no episodes in the last 6 months), ii)
improvement (reduction of more then 30% of fever epi-
sodes) iii) stationary iv) worsening (increase frequency
of fever episodes or appearance of new major clinical
manifestation).The Child Health Questionnaire (CHQ-
PF 50) was used to assess the health related quality of
life (HRQL). An international sample of 3315 healthy
children (52.2% female), with a mean (SD) age of 11.2
(3.8) years constituted the healthy control group.
Results
Data on follow-up are available for 31 patients. The
mean follow-up was 12.9 years (range 2.3-38.2). Steroid
on demand was effective in treating fever episodes. 15
patients showed a significant spontaneous reduction of
the frequency of fever episodes. Complete resolution
was observed in 3 patients. In 9 patients the disease was
stable, in 4 worsened. When compared to healthy age-
matched individuals, HRQL of MKD patients was gener-
ally affected, particularly for global health, general health
perception, mental health, parental-impact emotion and
self-esteem (p < 0.001).
Conclusions
Even if a relevant percentage of MKD patient show a
spontaneous amelioration of the disease, most of them
display a tendency towards a persistence of fever epi-
sodes that significantly affect their quality of life.
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